Heidelberg Pharma AG
XETRA:HPHA
Operating Margin
Heidelberg Pharma AG
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| DE |
|
Heidelberg Pharma AG
XETRA:HPHA
|
124.4m EUR |
-240%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD |
29%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.8B USD |
22%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
133B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
131.5B USD |
40%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
124.3B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.4B USD |
30%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
37.6B USD |
-8%
|
Heidelberg Pharma AG
Glance View
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Heidelberg Pharma AG's most recent financial statements, the company has Operating Margin of -240.2%.
You don't have any saved screeners yet